source
- Eli Lilly to pursue FDA approval for obesity drug in obstructive sleep apnea after positive Phase 3 trialEli Lilly announced that it will seek regulatory approval for its obesity medication as a treatment for obstructive sleep apnea, following a successful Phase 3 study. The trial showed positive res…
- Novo’s IL-6 inhibitor ziltivekimab may target milder cardio-renal patients after Phase 3 missAt the American Heart Association meeting, investigators discussed new data on Novo Nordisk’s IL-6 inhibitor ziltivekimab, suggesting it could be studied in patients with less severe cardiovascular…